<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815800</url>
  </required_header>
  <id_info>
    <org_study_id>6312</org_study_id>
    <nct_id>NCT02815800</nct_id>
  </id_info>
  <brief_title>Efficacy of Ethnodyne Visio in Parkinson's Disease</brief_title>
  <acronym>ETHNOPARK</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ETHNODYNE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ETHNODYNE VISIO is a food supplement composed of an innovative plant-based active ingredient
      acting alongside vitamin B2. It is proposed in patients with visual problems. Based on
      clinical and experimental data, the investigators propose a pilot open study in order to test
      the efficacy of &quot;Ethnodyne visio&quot; in patients with Parkinson 's disease (PD). The hypothesis
      is that Ethnodyne visio may improve motor and non motor signs of PD. 24 patients with PD will
      be evaluated before and after 3 months of add on treatment by Ethnodyne visio.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2016</start_date>
  <completion_date type="Actual">March 12, 2018</completion_date>
  <primary_completion_date type="Actual">March 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MDS UPDRS III score</measure>
    <time_frame>baseline and following 3 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in MDS UPDRS I, II and IV score</measure>
    <time_frame>baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levodopa equivalent dose treatment (equivalence table)</measure>
    <time_frame>baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, seriousness and severity of adverse event reactions</measure>
    <time_frame>during the 3 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>ETHNODYNE VISIO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration 2 times a day of a dietary supplement, as add on therapy, in patients with Parkinson s disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ETHNODYNE VISIO</intervention_name>
    <arm_group_label>ETHNODYNE VISIO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Parkinson disease (PD) with at least 3 years of evolution

          -  Hoehn and Yahr score 2 or 3

          -  with moderate fluctuations (score 1 or 2 for item 3 score IV MSD UPDRS)

          -  with no modification in anti-parkinsonian drugs since at least 1 month

          -  minimental test &gt;24

        Exclusion Criteria:

          -  known intolerance to Ethnodyne visio

          -  woman of childbearing potential or breastfeeding

          -  anticipated anti-parkinsonian treatment modification during the 3 months of the study

          -  antidepressant or anxiolytic drugs modified within one month prior to inclusion visit

          -  other chronic disease

          -  concomitant participation in a another clinical trial

          -  Subject under legal guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Neurologie,HÃ´pital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Motor signs</keyword>
  <keyword>Non motor signs</keyword>
  <keyword>Fluctuations</keyword>
  <keyword>Open labelled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

